Trial
NCT04335006
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Breast Cancer
Intervention
Carelizumab
Why stopped
Sponsor R \& D Strategy Adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-06